Treatment with these mRNAs improved peptide vaccine responses and restored antitumour immunity in aged mice by increasing tumour-specific CD8<sup>+</sup> infiltration and clonal diversity and synergizing with immune checkpoint blockade. The gene discussed is CD8A; the disease is neoplasm.